文献速递淋巴瘤

丹麦全国人群研究中套细胞淋巴瘤继发中枢神经系统淋巴瘤的特征与危险因素

Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population-based study.
PubMed 文献 · Br J Haematol · 2025-08-08

该丹麦全国人群研究纳入2010-2022年确诊的873例套细胞淋巴瘤患者,10年继发中枢神经系统淋巴瘤累积发生率为3.8%。母细胞样/多形性亚型、Ki67≥30%和乳酸脱氢酶升高是危险因素,继发后中位无进展生存1.8个月、总生存2.4个月。

要点

  • 套细胞淋巴瘤10年继发中枢神经系统淋巴瘤累积发生率为3.8%(95%CI 2.4-5.2)。
  • 母细胞样/多形性亚型、Ki67≥30%和乳酸脱氢酶升高与继发中枢神经系统淋巴瘤风险相关。
  • 高CNS-IPI患者1年继发中枢神经系统淋巴瘤发生率为5.8%(95%CI 1.6-10.0)。

核心结论

  • 套细胞淋巴瘤继发中枢神经系统淋巴瘤罕见且生存极差。
  • 母细胞样/多形性亚型和高CNS-IPI识别出继发中枢神经系统淋巴瘤高风险患者,作者认为对这些患者可考虑 upfront 中枢神经系统受累筛查。

研究设计与样本

  • 丹麦全国人群队列研究,纳入2010-2022年丹麦确诊的套细胞淋巴瘤且诊断时无确认中枢神经系统受累的患者。
  • 数据来自丹麦国家淋巴瘤登记处和病历,共纳入873例患者,中位年龄70岁。

主要发现

  • 10年继发中枢神经系统淋巴瘤累积发生率为3.8%(95%CI 2.4-5.2)。
  • 继发中枢神经系统淋巴瘤危险因素:母细胞样/多形性套细胞淋巴瘤HR 3.55(95%CI 2.05-6.14),Ki67≥30% HR 5.47(95%CI 1.86-16.10),乳酸脱氢酶升高HR 4.35(95%CI 1.91-9.91)。
  • 母细胞样/多形性套细胞淋巴瘤患者5年继发中枢神经系统淋巴瘤累积发生率为9.9%(95%CI 4.0-15.7)。
  • 高CNS-IPI患者1年继发中枢神经系统淋巴瘤发生率为5.8%(95%CI 1.6-10.0)。
  • 继发中枢神经系统淋巴瘤后中位无进展生存1.8个月(95%CI 1.3-4.7),中位总生存2.4个月(95%CI 1.3-8.9)。

关键数值与推荐

  • 母细胞样/多形性套细胞淋巴瘤:HR 3.55(95%CI 2.05-6.14)。
  • Ki67≥30%:HR 5.47(95%CI 1.86-16.10)。
  • 乳酸脱氢酶升高:HR 4.35(95%CI 1.91-9.91)。
  • 母细胞样/多形性套细胞淋巴瘤患者5年继发中枢神经系统淋巴瘤累积发生率9.9%(95%CI 4.0-15.7)。
  • 高CNS-IPI患者1年继发中枢神经系统淋巴瘤发生率5.8%(95%CI 1.6-10.0)。

临床怎么用

  • 作者认为,对母细胞样/多形性亚型和高CNS-IPI的套细胞淋巴瘤患者可考虑 upfront 中枢神经系统受累筛查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Secondary central nervous system (CNS) lymphoma (SCNSL) in mantle cell lymphoma (MCL) is associated with dismal outcomes, and risk factors are not well documented. This population-based study reports the incidence of SCNSL, risk factors and survival. All patients diagnosed with MCL in Denmark in 2010-2022 without confirmed CNS involvement at diagnosis were included. Data were retrieved from the Danish National Lymphoma Registry and medical records. In total, 873 patients (median age 70 years) were included. The 10-year cumulative incidence of SCNSL was 3.8% (95% confidence interval [CI] 2.4-5.2). Risk factors for SCNSL were blastoid/pleomorphic MCL (hazard ratio [HR] 3.55, 95% CI 2.05-6.14), Ki67 ≥30% (HR 5.47, 95% CI 1.86-16.10) and elevated lactatedehydrogenase (HR 4.35, 95% CI 1.91-9.91). The 5-year cumulative incidence of SCNSL for patients with blastoid/pleomorphic MCL was 9.9% (95% CI 4.0-15.7). Patients with high CNS international prognostic index (CNS-IPI) had a high 1-year incidence of SCNSL of 5.8% (95% CI 1.6-10.0). Median progression-free survival and overall survival were 1.8 months (95% CI 1.3-4.7) and 2.4 months (95% CI 1.3-8.9). In conclusion, SCNSL of MCL is rare and associated with poor survival. Blastoid/pleomorphic subtype and high CNS-IPI identified patients at high risk of SCNSL for whom upfront screening for CNS involvement should be considered.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Trab T, Ranadóttir T, Chanchiri I, et al. Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population-based study. Br J Haematol. 2025. PMID: 40781827. doi:10.1111/bjh.70082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。